New pill plus immunotherapy shows promise for Hard-to-Treat cancers

NCT ID NCT04130516

Ongoing Disease control Sponsor: Linnaeus Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This study tests a new oral drug called LNS8801, alone or combined with the immunotherapy pembrolizumab (Keytruda), in up to 200 adults with advanced solid tumors that have spread. The goal is to find a safe dose and see if the drug shrinks tumors. It is an early-stage trial, so the main focus is on safety and how the body processes the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LNS8801 (a drug taken by mouth that activates a protein called GPER) and pembrolizumab (an immunotherapy drug, also known as Keytruda)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of patients, so the drug may not prove effective or safe enough for wider use. Side effects are unknown at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer cutaneous melanoma gastric cancer gastric neoplasm lymphoma malignant pancreatic neoplasm melanoma neoplasm non-small cell lung carcinoma uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR, ADULT

Contacts and locations

Locations

Cedars-Sinai Medical Center

Los Angeles, California, 90048, United States
Columbia University Herbert Irving Comprehensive Cancer Center

New York, New York, 10032, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
The START Center for Cancer Care

San Antonio, Texas, 78229, United States
Thomas Jefferson University, Sidney Kimmel Cancer Center

Philadelphia, Pennsylvania, 19107, United States
University of New Mexico Comprehensive Cancer Center

Albuquerque, New Mexico, 87106, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19106, United States
Yale Cancer Center

New Haven, Connecticut, 06519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.